About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT03566472

The Blood Glucose Control in Patients With Type 2 Diabetes Treated With Glargine

Glargine is commonly used in insulin supplemental therapy in patients with type 2 diabetes(T2D) at present. This study aims to investigate the current status of blood glucose control in patients with ...

Lead sponsor: Nanjing First Hospital, Nanjing Medical University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Ma Jianhua

CONTACT

8625-52887092 majianhua196503@126.com

Sponsors

Lead Sponsor

Nanjing First Hospital, Nanjing Medical University

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Patients with T2DM, which was defined bypublished Criteria of World Health Organization in 1999;
•2. Patients were using glargine with or without oral hypoglycemic drugs and having a stable dose of glargine for more than 2 month would be recruited into this study;
•3. Patients had relatively constant diet and exercise in 2 month before the study;
•4. Fasting blood glucose was between 6.1 and 16mmolL, and postprandial (or random) blood glucose \<22.2mmol/L.

Exclusion Criteria

•1. Patients with severe cardiovascular diseases, such as stroke, transient ischemic attack, myocardial infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary intervention, and heart failure;
•2. Patients with severe infectious diseases;
•3. Patients with acute complications of diabetes on admission, such as diabetic ketoacidosis, diabetic hyperosmolar nonketotic coma, and lactic acidosis;
•4. Patients with history of psychiatric disorders and were unsuitable to use CGMS;
•5. Any other situations that made patients unsuitable to participate in the study, such as alcoholism and drug abuse.

Related studies

Clinical Study to Assess the Safety, Efficacy and In-Use Tolerability of Herbal-Based Sugar Support Effervescent Tablets in Type-2 Diabetes Mellitus Patients

NCT06961019 · Type2 Diabetes Mellitus

A Causative Role for Amylin in Diabetic Peripheral Neuropathy

NCT03481283 · Type2 Diabetes, Peripheral Neuropathy

Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)

NCT05277558 · Type2 Diabetes, Type 2 Diabetes Mellitus in Obese, and more

UK Imaging Diabetes Study Seeing Diabetes Clearly

NCT05057403 · Type2 Diabetes

Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins

NCT04564391 · Type2 Diabetes, NAFLD

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 11, 2019Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment100

Start dateJun 2018

Last updatedJun 11, 2019

Condition

Locations shown

Nanjing First Hostital

Nanjing, Jiangsu

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 11, 2019Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions